Literature DB >> 24370622

Apolipoprotein E alleles in Cuban patients with mild cognitive impairment.

Viana Manrique Suárez1, Yuriem Fernández, Elena del Carmen Ruiz López, David Higginson Clarke, Maria Antonieta Bobes, Ana Maria Riverón, Lilia López-Cánovas.   

Abstract

BACKGROUND: Apolipoprotein E (ApoE) ε4 genotype is the most clearly documented risk factor for Alzheimer's disease (AD). Epidemiological studies demonstrate an accelerated rate of progression to dementia and AD in patients with mild cognitive impairment (MCI). We assessed the ApoE allele and genotypes frequencies in Cuban patients with MCI.
METHODS: We performed ApoE genotyping of 74 Cuban patients more than 65 years old. Cognitive assessments included the Mini-Mental State Examination (MMSE) and a cognitive battery for evaluating memory, attention, perception, and executive function.
RESULTS: Cognitive impairments were characterized by amnesia and executive deficits in patients with MCI. The Apo ε4 allele frequency was 0.196 in patients with MCI, 10-fold higher than that in the controls. Patients carrying the ε4 allele exhibited poorer performance in MMSE and tests assessing executive function and short-term memory than noncarriers.
CONCLUSIONS: The patients exhibited amnestic MCI multiple domains. Cognitive performance was worse in patients who carried the ApoE ε4 allele.

Entities:  

Keywords:  Alzheimer’s disease; apolipoprotein E; cognitive domain; cognitive impairment; gen polymorphism

Mesh:

Substances:

Year:  2013        PMID: 24370622     DOI: 10.1177/1533317513517037

Source DB:  PubMed          Journal:  Am J Alzheimers Dis Other Demen        ISSN: 1533-3175            Impact factor:   2.035


  1 in total

1.  The Specific Impact of Apolipoprotein E Epsilon 2 on Cognition and Brain Function in Cognitively Normal Elders and Mild Cognitive Impairment Patients.

Authors:  Liang Gong; Ronghua Xu; Duan Liu; Lin Lan; Bei Zhang; Chuantao Zhang
Journal:  Front Aging Neurosci       Date:  2020-01-28       Impact factor: 5.750

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.